200
Views
13
CrossRef citations to date
0
Altmetric
Articles

P-Glycoprotein (P-170) expression in acute leukemias

, , &
Pages 35-41 | Published online: 04 Sep 2013

References

  • Arai Y, Masuda M, Sugawara I, Arai T, Motoji T, Tsuruo T, Oshimi K, Mizoguchi H. Expression of the MDR-1 and MDR-3 gene products in acute and chronic leukemias. Leuk Res 1997;4:313.
  • Bines S, Coon J, Gebel H, Chong A, Wang Y, Economou S. MDR function in lymphocyte subpopulations. Proc ASCO 1991;10:81.
  • Bradley G, Jurunka PF, Ling V. Mechanisms of multidrug resistance. Biochem Biophys Acta 1988;948:87.
  • Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D. Clinical significance of multidrug resistance P-Glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992;79:473.
  • Cumber PM, Jacobs A, Hoy T, Fisher J, Whittaker JA, Tsuruo T, Padua RA. Expression of the multiple drug resistance gene (mdr-1) and epitope masking in chronic lymphatic leukemia. Br J Haematol 1990;76: 226.
  • Epstein J, Hiao H, Oba BK. P-plycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 1989;74:913.
  • Filipites M, Suchomel RW, Lechner K, Pirker R. Immuno-cytochemical detection of the multidrug resistance associated protein and p-glycoprotein in acute myeloid leukemia, impact of antibodies, sample source and disease status. Leukemia 1997;11:1073.
  • Gruber S, Vitols S, Norgren I, Arestrom C, Peterson M, Bjorkholm P, Reizenstein P, Luthman H. Quantitative determination of mdr-1 gene expression in leukemic cells from patients with acute leukemia. Br J Cancer 1992;66:266.
  • Haber DA. Multidrug resistance (1v1DR-1) in leukemia, Is it time to test? Blood 1992;79:295.
  • Hirose M, Hosoi E, Hamano S, Jalili A. Multidrug resistance in hematological malignancy. Med Investig 2003;50:126–135.
  • Huet S, Marie JP, Gualde N, Robert N. Reference method for detection of mediated multidrug resistance in human hematological malignancies: a method validated by the laboratories of the French drug resistance network. Cytometry 1998;34:248.
  • Ito Y, Tanimoto M, Kumazawa T, Okumura M, Morishima Y, Ohno R, Saito H. Increased P-glycoprotein expression and multidrug resistance (mdr-1) gene amplification are infre-quently found in fresh acuted leukemia cells. Cancer 1989;63: 1534.
  • Kamel AM, El-Sharkawy NM, Shaaban K, Yassin DA, Sidhom I, Abo El-Naga S, El-hattab O. MDR expression and functional assay have no empact on survival in Egyptian pediatric acute leukemia. The Hematol J 2003;4\(Suppl. 2):35.
  • Kato S, Ideguchi H, Muta K, Nishimura J, Nawata H. Absence of correlation between cytotoxicity and drug transport by P-glycoprotein in clinical leukemic cells. Eur J Haematol 1991;47:146.
  • Koker MY, Guc D, Dogan AL, Kars A. Analysis of expression of P-glycoprotein by RT-PCR in hematological malignancies. The Hematol J (EHA) 2001;1\(Suppl. 1):268.
  • Kuwazuru Y, Yoshimuro A, Hanada S, Utsunomiya A, Makin° T, Ishibashi K, Kodam M, Iwahashi M, Arima T, Akiyama S. Expression of the multidrug transport P-glycoprotein in acute leukemia cells and correlation to clinical drug resistance. Cancer 1990;66:868.
  • Lamy T, Drenou B, Grulois I, Fardel O, Jacquelinet C, Goasguen J, Dauriac C, Amiot L, Bernard M, Fauchet R. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay. Leukemia 1995;9:1549.
  • Legrand O, Simonin G, Perrot J, Zittoun R, Marie J. P-gp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998;91:4480.
  • Li J, Xia Hua D, Wang W, Chen Z, Ruan C. Clinical and biologiocal relevance of flow cytometric determination of p-glycoprotein expression in acute non lymphocytic leukemia. Chin Med J 1997;110:919.
  • Michieli M, Damiani D, Ermacora A, Raspadura D, Michelutti A, Grimaz S, Fanin R, Russo D, Lauria F, Masalini P, Baccarani M. P-glycoprotein (PGP).and lung resistance related protein (LRP) expression and function in leukemic blast cells. Br J Haematal 1997;96:356.
  • Nussler V, Pelka-Fleischer R, Zwierzina H, Nerl C, Beckert B, Cieseler F, Diem H. P-glycoprotein expression in patients with acute leukemia. Leukemia 1996;10 (Suppl. 3):S23–S31.
  • Pall G, Spitaler M, Hoffmann J, Thaler J, Ludescher C. Multidrug resistance in acute leukemia. A comparison of different diagnostic methods. Leukemia 1997;11:1067.
  • Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L, Ludwig H, Lechner K. MDR-1 gene expression and treatment outcome in acute myeloid leukemia. J Nat Cancer Inst 1991;83:708.
  • Rothenberg ML, Mickley LA, Cole DE, Balis FM, Tsuruo T, Fajo AT. Expression of the mdr-1/p-170 gene in patients with acute lymphoblastic leukemia. Blood 1989;74:1388.
  • Sallam TMH, El-Sewefy D, Hindawy D, Abd El-Maksoud S, Osman A. P- Glycoprotein and lung resistance related protein expression in childhood acute lymphoblastic leukemia. Egypt J Hematol 2002;715:733.
  • Salmon SE, Grogan TM, Miller T, Sheper R, Dalton WA. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma and breast cancer by p-glycoprotein staining. JNCI 1989;81: 696.
  • Sato H, Gottesman MM, Golstein LJ, Pastan I, Block AM, Sandberg AA, Preisler HD. Expression of multidrug resistance gene in myeloid leukemias. Leuk Res 1990;14:11.
  • Senent L, Jarque I, Martin G, Sempere A, Gonzalez-Garcia Y, Gomis F, Perez-Sirvent M, Dele Rubia J, Sanz MA. P-glycoprotein expression and prognostic value in acute myeloid leukemia. Haematologica 1998;83:783.
  • Solary E, Bidan JM, Calvo F, Chauffert B, Caillot D, Mugneret F, Gauville C, Tsuro T, Carli P, Guy H. P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukemia and myeloma. Leukemia 1991;5:592.
  • Tafuri A, Sommaggio A, Burba L, Aibergoni MP, Petrucci MT, Mascolo MG, Testi AM, Basso G. Prognostic value of rhodamine-efflux and MDR-1/p-170 expression in childhood acute leukemia. Leuk Res 1995;19:927.
  • Tafuri A, Gregorj C, Petrucci MT. MDR, protein expression is an independant predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2002;100:974.
  • Te Boeldiorst PAW, de-Leeuw K, Schoester M, Wittebol S, Nooter K, Hagemeijer A, Lowenberg B, Sonneveld P. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid cells. Blood 1993;82: 3157.
  • Vanbeck WP, Smets LA, Emmlo T. Increased sialic acid density in surface glycoprotein of transformed malignant cells: A general phenomenon. Cancer Res 1973;33: 2913.
  • Wuchter C, Leonid K, Ruppert V, Schrappe M, Buchner T, Schoch C, Haferlach T, Harbott J, Ratei R, Dorken B, Ludwig WD. Clinical significance of p-glycoportein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 2000;85:711.
  • Yogesswaran G, Salk P. Metastatic potential is positively correlated with cell surface sialylation of cultured murine cells. Science 1981;212:1514.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.